Skye Bioscience, Inc.
SKYE
$1.91
$0.094.95%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -120.51% | 84.37% | -153.99% | 2.86% | 55.32% |
| Total Depreciation and Amortization | 517.25% | 129.17% | -12.09% | -16.87% | -9.84% |
| Total Amortization of Deferred Charges | -100.00% | 8.89% | -- | -- | 2,400.00% |
| Total Other Non-Cash Items | 427.45% | -112.29% | 1,465.54% | -25.64% | -93.41% |
| Change in Net Operating Assets | -686.08% | 282.91% | -263.37% | -78.89% | 92.86% |
| Cash from Operations | -112.58% | -29.79% | -256.14% | -15.94% | 21.08% |
| Capital Expenditure | -614.29% | -40,937.84% | -- | -68.42% | 91.14% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -79.30% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -100.00% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 1,391.43% | -234.70% | -- | -79.35% | -100.12% |
| Total Debt Issued | -- | -- | -- | -- | -100.00% |
| Total Debt Repaid | -- | -- | -- | -- | 96.49% |
| Issuance of Common Stock | 2,329.31% | -100.00% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -2,327.16% | -- | -- | -- | -- |
| Cash from Financing | 124.67% | -100.00% | -1,598.62% | 189,178.59% | -166.37% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -108.47% | -149.13% | -335.99% | 5,663.69% | -567.30% |